Autoantigen TRIM21/Ro52 is expressed on the surface of antigen-presenting cells and its enhanced expression in Sjögren’s syndrome is associated with B cell hyperactivity and type I interferon activity

• Timothy R D J Radstake,
• Joel A G van Roon,
• Maarten R Hillen,
• Sofie L M Blokland,
• Aridaman Pandit,
• Katia Urso,
• Emma Koppe,
• Ana Pinheiro Lopes,
• Tom Slocombe,
• André van Maurik

Affiliations

Timothy R D J Radstake

Centre for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

Joel A G van Roon

Centre for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

Maarten R Hillen

Centre for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

Sofie L M Blokland

Centre for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

Aridaman Pandit

Centre for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

Katia Urso

GSK Immunology Network and Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK

Emma Koppe

GSK Immunology Network and Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK

Ana Pinheiro Lopes

Centre for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands

Tom Slocombe

GSK Immunology Network and Adaptive Immunity Research Unit, GlaxoSmithKline, Stevenage, UK

André van Maurik

Clinical Pharmacology and Experimental Medicine, GlaxoSmithKline, Stevenage, UK